top of page

Portfolio

The ATG Project is providing access to an extensive and expanding portfolio of safe and innovative technologies. With this portfolio, ATG can help partners accelerate the advancement of cutting edge therapeutics for the treatment of rare and ultra-rare diseases. Learn about how ATG can help access the growing library of technologies by contacting us at access@theatgproject.org.​​

Treat
More Patients.

IgM_ATG Banner.png

Anti-AAV antibodies limit patient access to gene therapies. Notably, immunoglobulin G and M are major antibody subtypes that neutralize AAV capsids and can trigger unwanted side effects. 

 

Antibody cleaving enzymes are an innovative platform technology that can safely, rapidly and transiently help clear antibodies from the blood circulation. ATG is working to bring this gene therapy pre-treatment regimen to otherwise ineligible patients with pre-existing immunity. 

Lower
the
Dose.

Vector dose-limiting toxicity is a significant challenge for AAV gene therapy.

​

High potency AAV capsids can enable treatment at lower vector doses enabling greater patient safety. ATG is working to bring safe and potent AAV vectors to patients with the goal of enabling gene therapy approaches for metabolic, neurologic, cardiovascular, and kidney diseases.

bottom of page